Publications
View publications of the A-TANGO consortium or individual consortium members as well as background literature. Once new publications are available, we list them here. Open-access papers are linked directly to the full-text version. All others lead to the respective journal repository or publisher. For A-TANGO press releases, visit the Downloads page. To receive our project newsletter, subscribe here!
A-TANGO Publications (count: 4)
-
- Greverath LM et al. (2025). Exploring the effects of serum G-CSF levels in acute-on-chronic liver failure (ACLF): Insights from a post hoc analysis of the GRAFT study Journal of Hepatology, Volume 82, Issue 6: pp. e288–e290
More2025 -
- Kiourtis C et al. (2024). Hepatocellular senescence induces multi-organ senescence and dysfunction via TGFβ Nature Cell Biology, Volume 26: pp. 2075–2083
2024 -
- Engelmann C et al. (2022). Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF Journal of Hepatology. Volume 77, Issue 5: pp. 1325-1338
2022
Background Reading
- Arroyo V et al. (2016). Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers, 2: 16041.
- Arroyo V et al. (2015). Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. J Hepatol, 62: S131-143.
- Claria J, Arroyo V, and Moreau R. (2016). The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray. J Immunol, 197: 3755-3761.
- Claria J et al. (2016). Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology 64: 1249-1264.
- Di Campli C et al. (2007). Safety and efficacy profile of G-CSF therapy in patients with acute-on-chronic liver failure. Dig Liver Dis, 39: 1071-1076.
- Engelmann C et al. (2020). Recombinant Alkaline Phosphatase Prevents Acute on Chronic Liver Failure. Sci Rep, 10: 389.
- Engelmann C et al. (2020). Toll-like receptor 4 inhibition acts synergistically with G-CSF to prevent organ injury and to induce regeneration in acute-on-chronic liver failure. J Hepatol, 73: Supplement 1, S28.
- Engelmann C et al. (2021).Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study). J Hepatol, 75(6): 1346-1354.
- Engelmann C et al. (2020). Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure. J Hepatol, 73(1): 102-112.
- Gaia S et al. (2006). Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease. J Hepatol, 45: 13-19.
- Gustot T et al. (2015). Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology, 62: 243-252.
- Jalan R et al. (2014). Toward an improved definition of acute-on-chronic liver failure. Gastroenterology, 147: 4-10.
- Jalan R et al. (2015). The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol, 62: 831-840.
- Moreau R et al. (2013). Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology, 144: 1426-1437.
- Prajapati R et al. (2017). Granulocyte colony-stimulating factor improves survival of patients with decompensated cirrhosis: a randomized-controlled trial. Eur J Gastroenterol Hepatol, 29: 448-455.
- Rice TW et al. (2010). A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med, 38: 1685-1694.
- Takashima K et al. (2009). Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol, 157: 1250-1262.